Global Non-invasive Prenatal Testing Market Report 2022 – Market Forecast, Trends And Strategies

11 Feb, 2022

The global non-invasive prenatal testing market size is expected to grow from $3.67 billion in 2021 to $4.21 billion in 2022 at a compound annual growth rate (CAGR) of 14.8%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The non-invasive prenatal testing market is expected to reach $7.34 billion in 2026 at a CAGR of 14.9%.

What is the Global Non-invasive Prenatal Testing Market?

The non-invasive prenatal testing market consists of sales of non-invasive prenatal testing kits, instruments and related services. Non-invasive prenatal testing kits and equipment are used to diagnose genetic abnormalities, mainly chromosome defects in fetus in first trimester of pregnancy. Non-invasive prenatal testing includes ultrasound detection, fetal cells in maternal blood tests, cell-free DNA in maternal plasma tests and biochemical screening tests.

Get a Sample of the global non-invasive prenatal testing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2492&&type=smp

What drives the Global Non-invasive Prenatal Testing Market?

High incidence rate of Down syndrome is one major factor driving non-invasive prenatal testing (NIPT) market with increase in average maternal age which has led to a concern on the safety about the growth of the fetus. Down syndrome is a chromosomal condition that occurs when an error in cell division results in an extra chromosome 21 and can affect the fetus cognitive ability and physical growth. The NIPT screening tests do not harm the mother or baby, carries no risk of miscarriage as they are non-invasive, and can detect more than 99% of cases of Down syndrome. According to National Down Syndrome Society and Centres for Disease control and Prevention, in the USA, 1 in every 700 babies are born with Down syndrome and 80% of children with Down syndrome are born to older mothers. The increased risk of having babies with Down syndrome among older women drives the non-invasive prenatal testing market.

Get the full global non-invasive prenatal testing industry report here:

https://www.thebusinessresearchcompany.com/report/non-invasive-prenatal-testing-global-market

Global Non-invasive Prenatal Testing Market Segments
The global non-invasive prenatal testing market is segmented:
By Type: Consumables, Instruments
By End User: Hospital, Diagnostic Labs
By Instruments: NGS Systems, PCR Instruments, Microarrays, Ultrasound Devices, Others (Centrifuges, UV Systems, Incubators, Microscopes)
By Consumables: Assay Kits and Reagents, Disposables
By Application: Trisomy, Microdeletion, Genetics, Rh Factor
By Geography: The regions covered in the non-invasive prenatal testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Non-invasive Prenatal Testing Global Market Report 2022provides market size and growth forecasts for the global non-invasive prenatal testing market, global non-invasive prenatal testing market share, non-invasive prenatal testing market segments and geographies, non-invasive prenatal testing market competitive landscape including leading competitors’ revenues, profiles and market shares. The non-invasive prenatal testing market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Global Non-invasive Prenatal Testing Industry Playersinclude F. Hoffmann-La Roche AG, IlluminaInc., Laboratory Corporation of America Holdings, NateraInc., PerkinElmerInc., Quest Diagnostics Incorporated, Agilent TechnologiesInc, BGI Diagnosis, Berry Genomics Co., Ltd, LifeCodexx AG, Myriad GeneticsInc., NIPD Genetics, SequenomInc., Annoroad Gene Technology, Centogene AG, CounsylInc., EUROFINS Genoma Group, Eurofins Scientific, Next Biosciences, Premaitha Health Plc, Ariosa Diagnostics (Roche), Premaitha Health, Beijing Genomics Institute, Yourgene Health PLC, GE Healthcare, Koninklijke Philips N.V., Thermo Fisher ScientificInc., Pacific Biosciences of CaliforniaInc., and QIAGEN N.V. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.